Scalper1 News
Biotech Bluebird Bio plunged to a 52-week low Monday after the latest data on its gene therapy for severe anemia failed to live up to the promise of earlier data, leading to several downgrades. On Sunday at the annual American Society of Hematology (ASH) conference, Bluebird (BLUE) detailed its early-stage findings on patients with sickle-cell disease (SCD) and beta-thalassemia, two genetic diseases that cause anemia, who were treated with its Scalper1 News
Scalper1 News